{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:29:27Z","timestamp":1771558167483,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","jognn.awhonn.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetric, Gynecologic, & Neonatal Nursing"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jogn.2025.05.114","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:06:16Z","timestamp":1748563576000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strategies to Reduce the Risk-Adverse Reproductive Outcomes Related to Hazardous Drugs"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1756-4262","authenticated-orcid":false,"given":"AnnMarie L.","family":"Walton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-5496","authenticated-orcid":false,"given":"MiKaela M.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jogn.2025.05.114_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/21650799221140583","article-title":"The factors that influence chemotherapy exposure among nurses: An integrative review","volume":"71","author":"Abu-Alhaija","year":"2023","journal-title":"Workplace Health Safety"},{"issue":"4","key":"10.1016\/j.jogn.2025.05.114_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijheh.2017.03.005","article-title":"Antineoplastic drug residues inside homes of chemotherapy patients","volume":"220","author":"Bohlandt","year":"2017","journal-title":"International Journal of Hygiene and Environmental Health"},{"issue":"2","key":"10.1016\/j.jogn.2025.05.114_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1078155221992103","article-title":"Surface contamination with nine antineoplastic drugs in 109 Canadian centers: 10 years of a monitoring program","volume":"28","author":"Chabut","year":"2022","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"17","key":"10.1016\/j.jogn.2025.05.114_bib5","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/ajhp\/zxab134","article-title":"Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination","volume":"78","author":"Gabay","year":"2021","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"4","key":"10.1016\/j.jogn.2025.05.114_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0890334413479671","article-title":"Duration of cisplatin excretion in breast milk","volume":"29","author":"Hays","year":"2013","journal-title":"Journal of Human Lactation"},{"issue":"5","key":"10.1016\/j.jogn.2025.05.114_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.18773\/austprescr.2015.056","article-title":"Drugs in breastfeeding","volume":"38","author":"Hotham","year":"2015","journal-title":"Australian Prescriber"},{"key":"10.1016\/j.jogn.2025.05.114_bib8","series-title":"IARC monographs on the identification of carcinogenic hazards to humans","year":"2025"},{"issue":"5","key":"10.1016\/j.jogn.2025.05.114_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41416-019-0529-z","article-title":"Breast milk paclitaxel excretion following intravenous chemotherapy\u2014A case report","volume":"121","author":"Jackson","year":"2019","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1016\/j.jogn.2025.05.114_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/bfm.2020.29157.hmj","article-title":"ABM Clinical Protocol #34: Breast cancer and breastfeeding","volume":"15","author":"Johnson","year":"2020","journal-title":"Breastfeeding Medicine"},{"issue":"1","key":"10.1016\/j.jogn.2025.05.114_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/01.NAJ.0000552583.69729.51","article-title":"Antineoplastic drug administration by pregnant and nonpregnant nurses: An exploration of the use of protective gloves and gowns","volume":"119","author":"Lawson","year":"2019","journal-title":"American Journal of Nursing"},{"issue":"4","key":"10.1016\/j.jogn.2025.05.114_bib12","doi-asserted-by":"crossref","first-page":"327.e1","DOI":"10.1016\/j.ajog.2011.12.030","article-title":"Occupational exposures among nurses and risk of spontaneous abortion","volume":"206","author":"Lawson","year":"2012","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1016\/j.jogn.2025.05.114_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.annepidem.2020.09.003","article-title":"Prepregnancy handling of antineoplastic drugs and risk of miscarriage in female nurses","volume":"53","author":"Nassan","year":"2021","journal-title":"Annals of Epidemiology"},{"key":"10.1016\/j.jogn.2025.05.114_bib15","series-title":"NTP monograph: Developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy","year":"2013"},{"key":"10.1016\/j.jogn.2025.05.114_bib16","series-title":"NTP monograph on the systematic review of occupational exposure to cancer chemotherapy agents and adverse health outcomes","year":"2019"},{"key":"10.1016\/j.jogn.2025.05.114_bib17","series-title":"Chemotherapy and immunotherapy guidelines and recommendations for practice","year":"2023"},{"key":"10.1016\/j.jogn.2025.05.114_bib18","series-title":"Safe handling of hazardous drugs","year":"2024"},{"key":"10.1016\/j.jogn.2025.05.114_bib19","series-title":"NIOSH list of hazardous drugs in healthcare settings","author":"Ovesen","year":"2024"},{"issue":"5","key":"10.1016\/j.jogn.2025.05.114_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000859","article-title":"First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: A case study","volume":"5","author":"Peccatori","year":"2020","journal-title":"ESMO Open"},{"issue":"24","key":"10.1016\/j.jogn.2025.05.114_bib21","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.2146\/ajhp180564","article-title":"ASHP guidelines on handling hazardous drugs","volume":"74","author":"Power","year":"2018","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"3","key":"10.1016\/j.jogn.2025.05.114_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1006\/rtph.2002.1558","article-title":"Differential sensitivity of children and adults to chemical toxicity: I. Biological basis","volume":"35","author":"Scheuplein","year":"2002","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"8","key":"10.1016\/j.jogn.2025.05.114_bib23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/bdra.23063","article-title":"Cancer chemotherapeutic agents as human teratogens","volume":"94","author":"Selig","year":"2012","journal-title":"Birth Defects Research A"},{"issue":"5","key":"10.1016\/j.jogn.2025.05.114_bib24","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/1078155218783538","article-title":"Field evaluation of onsite near real-time monitors for surface contamination by 5-fluorouracil","volume":"25","author":"Smith","year":"2019","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"4","key":"10.1016\/j.jogn.2025.05.114_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1066-7938(00)80085-8","article-title":"The precautionary principle: A framework for sustainable business decision-making","volume":"5","author":"Tickner","year":"1998","journal-title":"Corporate Environmental Strategy"},{"issue":"3","key":"10.1016\/j.jogn.2025.05.114_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1188\/20.ONF.263-272","article-title":"Surface contamination with antineoplastic drugs on two inpatient oncology units","volume":"47","author":"Walton","year":"2020","journal-title":"Oncology Nursing Forum"},{"key":"10.1016\/j.jogn.2025.05.114_bib30","series-title":"Journal of Occupational and Environmental Hygiene","article-title":"A scoping review of surface wipe sampling for antineoplastic drug contamination in patient care areas","author":"Walton","year":"2025"},{"key":"10.1016\/j.jogn.2025.05.114_bib31","article-title":"Procedures for developing the NIOSH list of hazardous drugs in healthcare settings","author":"Whittaker","year":"2023","journal-title":"National Institute for Occupational Safety and Health"},{"issue":"6","key":"10.1016\/j.jogn.2025.05.114_bib32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1188\/15.ONF.42-06AP","article-title":"Secondary exposure of family members to cyclophosphamide after chemotherapy of outpatients with cancer: A pilot study","volume":"42","author":"Yuki","year":"2015","journal-title":"Oncology Nursing Forum"}],"container-title":["Journal of Obstetric, Gynecologic, & Neonatal Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0884217525001844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0884217525001844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:13:15Z","timestamp":1767888795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0884217525001844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0884217525001844"],"URL":"https:\/\/doi.org\/10.1016\/j.jogn.2025.05.114","relation":{},"ISSN":["0884-2175"],"issn-type":[{"value":"0884-2175","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to Reduce the Risk-Adverse Reproductive Outcomes Related to Hazardous Drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetric, Gynecologic, & Neonatal Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogn.2025.05.114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Association of Women\u2019s Health, Obstetric and Neonatal Nurses. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}